1887

Abstract

Invasive meningococcal disease (IMD) is a major cause of meningitis and septicaemia worldwide. The switches in serogroup predominance contribute to the unpredictable nature of the disease with significant health impacts. The aim of this study was to determine the epidemiological profile of IMD in Rio Grande do Sul, Santa Catarina and Paraná, three states in the south of Brazil. All meningitis cases confirmed by clinical and/or laboratory criteria notified to the national information system for notifiable diseases between 2015 and 2019 were analysed. Proportions of serogroup and incidence by age were calculated. A total of 17 894 cases of IMD were reported during this period. Of these, 9029 cases (50 %) were due to serogroup C. Furthermore, serogroup W was responsible for almost half of the cases among children younger than 5 years old during 2017 and 2018, with an overall incidence of 33.3 cases per 100 000 infants. Despite the reduction in serogroup C after the introduction of meningococcal C conjugate vaccine into a childhood immunization programme in Brazil, it remains a significant healthcare issue in the south of the country. Changes in disease epidemiology were observed and serogroup W was the most common among children below 5 years of age in 2017 and 2018. Although future cost-effectiveness studies are necessary, our results could have future implications for meningococcal vaccination programmes.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001323
2021-02-05
2021-02-26
Loading full text...

Full text loading...

References

  1. Villena R, Valenzuela MT, Bastías M, Santolaya ME. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine 2019; 37: 6915 6921 [CrossRef] [PubMed]
    [Google Scholar]
  2. Rémy V, Zöllner Y, Heckmann U. Vaccination: the cornerstone of an efficient healthcare system. J Mark Access Health Policy 2015; 3: 27041 [CrossRef] [PubMed]
    [Google Scholar]
  3. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 853 861 [CrossRef] [PubMed]
    [Google Scholar]
  4. Loenenbach AD, van der Ende A, de Melker HE, Sanders EAM, Knol MJ. The clinical picture and severity of invasive meningococcal disease serogroup W compared with other serogroups in the Netherlands, 2015-2018. Clin Infect Dis 2019
    [Google Scholar]
  5. Vespa Presa J, Abalos MG, Sini de Almeida R, Cane A. Epidemiological burden of meningococcal disease in Latin America: a systematic literature review. Int J Infect Dis 2019; 85: 37 48 [CrossRef] [PubMed]
    [Google Scholar]
  6. Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis 2013; 19: 566 573 [CrossRef] [PubMed]
    [Google Scholar]
  7. Serra L, Presa J, Christensen H, Trotter C. Carriage of Neisseria Meningitidis in low and middle income countries of the Americas and Asia: a review of the literature. Infect Dis Ther 2020; 9: 209 240 [CrossRef] [PubMed]
    [Google Scholar]
  8. Sáfadi MA, Bettinger JA, Maturana GM, Enwere G, Borrow R et al. Evolving meningococcal immunization strategies. Expert Rev Vaccines 2015; 14: 505 517 [CrossRef] [PubMed]
    [Google Scholar]
  9. Andrade AL, Minamisava R, Tomich LM, Lemos AP, Gorla MC et al. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil. Vaccine 2017; 35: 2025 2033 [CrossRef] [PubMed]
    [Google Scholar]
  10. Sáfadi MAP, O’Ryan M, Valenzuela Bravo MT, Brandileone MCC, Gorla MCO et al. The current situation of meningococcal disease in Latin America and updated global meningococcal initiative (GMI) recommendations. Vaccine 2015; 33: 6529 6536 [CrossRef] [PubMed]
    [Google Scholar]
  11. Presa JV, de Almeida RS, Spinardi JR, Cane A. Epidemiological burden of meningococcal disease in Brazil: a systematic literature review and database analysis. Int J Infect Dis 2019; 80: 137 146 [CrossRef] [PubMed]
    [Google Scholar]
  12. Chicuto LAD, de Moraes C, Cássio de Moraes J, Sáfadi MAP. A critical analysis of serogroup B meningococcal disease burden in Brazil (2001-2015): implications for public health decisions. Hum Vaccin Immunother 2020; 16: 1945 1950 [CrossRef] [PubMed]
    [Google Scholar]
  13. Moura Silveira M, McBride AJA, Trotter CL. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme. Vaccine 2019; 37: 6783 6786 [CrossRef] [PubMed]
    [Google Scholar]
  14. Baethgen LF, Weidlich L, Moraes C, Klein C, Nunes LS et al. Epidemiology of meningococcal disease in southern Brazil from 1995 to 2003, and molecular characterization of Neisseria meningitidis using multilocus sequence typing. Trop Med Int Health 2008; 13: 31 40 [CrossRef] [PubMed]
    [Google Scholar]
  15. Weidlich L, Baethgen LF, Mayer LW, Moraes C, Klein CC et al. High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in Southern Brazil. J Infect 2008; 57: 324 331 [CrossRef] [PubMed]
    [Google Scholar]
  16. Abad R, López EL, Debbag R, Vázquez JA. Serogroup W meningococcal disease: global spread and current affect on the southern cone in Latin America. Epidemiol Infect 2014; 142: 2461 2470 [CrossRef] [PubMed]
    [Google Scholar]
  17. de Cássia Campos Bertoncini R, André Herberts R, Goulart Dário M, Roberto Merlin C, Miletti LC. Epidemiological study of Neisseria meningitidis strains isolated from cases of meningococcal disease in Santa Catarina state, Brazil, 1987-2003. Public Health 2007; 121: 880 883 [CrossRef] [PubMed]
    [Google Scholar]
  18. Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8: 851 861 [CrossRef] [PubMed]
    [Google Scholar]
  19. de Soarez PC, Sartori AMC, de Andrade Lagoa Nóbrega L, Itria A, Novaes HMD, Novaes HMD. Cost-Effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil. Value Health 2011; 14: 1019 1027 [CrossRef] [PubMed]
    [Google Scholar]
  20. de Soárez PC, Sartori AMC, Freitas AC, Nishikawa Álvaro Mitsunori, Novaes HMD. Cost-Effectiveness analysis of universal vaccination of adults aged 60 years with 23-valent pneumococcal polysaccharide vaccine versus current practice in Brazil. PLoS One 2015; 10: e0130217 [CrossRef] [PubMed]
    [Google Scholar]
  21. van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Knol MJ, Stoof SP et al. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent Meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: a randomized controlled trial. Vaccine 2017; 35: 4745 4752 [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001323
Loading
/content/journal/jmm/10.1099/jmm.0.001323
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error